All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Podcast: Bringing diversity to Alzheimer’s trials

In recent years, the Alzheimer’s disease market has seen several developments, including the debut of the first disease-modifying therapies (DMTs),…
Definium’s psychedelic prospects brighten further on Phase III success

Definium Therapeutics has notched another late-stage win for DT120 in generalised anxiety disorder (GAD) – further bolstering the drug’s market…
Belenos’ Keymed licensing deal delivers on Phase II win in rhinosinusitis

Belenos Biosciences’ bet worth up to $185m on Keymed Biosciences’ subcutaneous chronic rhinosinusitis with nasal polyps (CRSwNP) therapy is showing…
Silence’s stock soars on divesiran’s Phase II polycythaemia vera success

British biotech Silence Therapeutics has been making noise on the stock markets by posting 30% growth in its share price…
Soligenix culls topical lymphoma asset after Phase III miss

Soligenix has terminated the late-stage development programme for its topical cutaneous T-cell lymphoma (CTCL) therapy, HyBryte, after the drug failed…

Context drops bispecific T-cell engager on cost-cutting initiative

Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the…
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data

MSD (Merck & Co) and Gilead Sciences have terminated a Phase III trial evaluating a duo of blockbuster oncology medicines…
MSD posts a victory and defeat for anti-TL1A in skin condition and rare lung disease

MSD (Merck & Co) has secured a win for its anti-TL1A hopeful, tulisokibart, in painful skin condition, hidradenitis suppurativa (HS),…
Rocket points to Danon gene therapy’s safety after Phase II protocol change

Rocket Pharmaceuticals has safely treated three patients with its one-time Danon disease gene therapy, RP-A501, during a Phase II study…
Moderna adds new cohort to Phase III vaccine trial after interim data miss

Moderna is looking to add an additional cohort to a late-stage study evaluating its norovirus vaccine hopeful, mRNA-1403, after the…